Which of the following components is NOT approved for obesity treatment in children?

The correct answer identifies Contrave as the component not approved for obesity treatment in children. Contrave is a combination medication that includes naltrexone and bupropion. While both ingredients have been studied for various uses in adults, the combination has not been studied or approved specifically for pediatric use in treating obesity.

In contrast, the other options have received some level of approval or endorsement for managing obesity in the pediatric population. Qsymia, which combines phentermine and topiramate, is approved for adolescents aged 12 years and older. Liraglutide, a GLP-1 receptor agonist, has been shown to be effective in treating obesity and is approved for use in children aged 12 and older as well. Phentermine, although primarily approved for short-term weight management in adults, is also sometimes used off-label in children, particularly for those with obesity when lifestyle interventions have not been successful.

Thus, this context highlights why Contrave is the only option that does not have approval for use in children for obesity treatment, setting it apart from the other listed medications.